Pfizer Inc. (NYSE:PFE) is one of the Cheap NYSE Stocks to Buy Now. On December 6, Pfizer Inc. (NYSE: PFE) announced results from its Phase 3 BASIS Study, which evaluates HYMPAVZI for people living with hemophilia A or B with inhibitors. The study included 48 adults and adolescents with severe hemophilia A or B. Patients treated with HYMPAVZI showed a 93% reduction in the annualized bleeding rate (ABR) compared to OD therapy. Management noted that HYMPAVZI is administered only once a week through subcutane ...

证券日报网讯 12月10日晚间，重药控股发布公告称，2025年12月9日，参股子公司药友制药与上海复星 医药产业发展有限公司及辉瑞共同签订《Collaboration and License Agreement》，主要就口服小分子胰 高血糖素样肽（GLP-1R）激动剂（含YP05002）及含有该活性成分的产品授予辉瑞全球独家开发、生 产及商业化权利，药友制药将获不可退还首付款15000万美元及至多35000万美元开发里程碑付款。 （编辑 丛可心） ...

This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter. Dive Brief: Elevance has added a former Pfizer executive to its board, the latest addition of pharmaceutical industry veteran as the insurer focuses on building its pharmacy services. Amy Schulman will start as an independent director of Elevance effective Jan. 12, the insurer announced Wednesday. Schulman will serve on the board’s audit and finance committ ...

Core Insights - The article highlights a significant licensing agreement between Fosun Pharma and Pfizer for the oral GLP-1 receptor agonist YP05002, marking a pivotal moment in the weight loss drug market [1][4][8] - The transaction, valued at over $2 billion, reflects the growing recognition of Chinese pharmaceutical innovation on the global stage [5][8] Group 1: Licensing Agreement Details - Fosun Pharma's subsidiary, Yaoyou Pharmaceutical, has entered into a licensing agreement with Pfizer, granting Pfizer exclusive global rights to develop, manufacture, and commercialize YP05002 [1] - Pfizer will pay an upfront fee of up to $150 million and is eligible for milestone payments totaling up to $1.935 billion [1] - This agreement is seen as a strategic move for Pfizer to re-enter the competitive GLP-1 market, where it has previously lagged [4][5] Group 2: Market Dynamics and Trends - The weight loss drug development landscape is becoming increasingly competitive, with multiple players exploring next-generation oral GLP-1 drugs that balance efficacy and tolerability [2][3] - Recent data from companies like Structure Therapeutics and Galmed Pharmaceuticals indicate promising results for oral GLP-1 candidates, highlighting the shift from injectable to oral formulations [2][3] - Innovative mechanisms, such as RNA interference therapies, are emerging as potential disruptors to existing GLP-1 treatments, targeting fat metabolism more effectively [3] Group 3: Implications for Chinese Pharmaceutical Innovation - The high upfront payment for YP05002 signifies a validation of the drug's potential and the quality of Chinese pharmaceutical research, moving beyond late-stage clinical data to earlier-stage partnerships [5][6] - Fosun Pharma's strategy includes a dual approach of "bringing in" and "going out," enhancing its innovation pipeline and pushing for international recognition of its research capabilities [6][7] - The transaction is indicative of a broader trend where Chinese companies are transitioning from being market followers to core contributors in global pharmaceutical innovation [8]

Core Viewpoint - The Invesco High Dividend Low Volatility ETF (SPHD) offers a 4.71% yield, significantly higher than the S&P 500, by investing in a concentrated portfolio of 50 U.S. stocks known for high dividend yields and low volatility [2][3]. Group 1: ETF Overview - SPHD has $3.1 billion in assets and a low expense ratio of 0.30%, focusing on defensive sectors such as utilities, REITs, healthcare, and consumer staples [2][8]. - The fund's income is derived from dividends paid by the underlying companies, making the sustainability of these payouts crucial for investors [2]. Group 2: Top Holdings Analysis - The top five holdings in SPHD account for approximately 14% of the portfolio, emphasizing established dividend payers across various sectors [4]. - Pfizer (PFE) yields 6.53% with a conservative payout ratio of 36.4% and has a history of 19 consecutive years of dividend increases, despite recent revenue declines in COVID-related products [5]. - Altria (MO) offers a 7.04% yield with a payout ratio of 77.9%, maintaining a 19-year dividend growth streak, although it faces long-term risks from declining tobacco volumes [6]. - Healthpeak Properties (DOC) has the highest yield at 7.14%, but it shows negative GAAP earnings; it should be evaluated based on funds from operations, which are projected to be between $1.78 and $1.84 per share [7].

Core Viewpoint - Pfizer is set to reduce its workforce in Switzerland as part of a broader multi-year cost reduction initiative [1] Group 1 - The job cuts will involve hundreds of positions within the company [1] - This decision is part of Pfizer's ongoing efforts to streamline operations and improve financial performance [1]

Pfizer is cutting hundreds of jobs in Switzerland as part of a multi-year program to reduce costs, according to people familiar with the matter. https://t.co/umjVHlAxPE ...

Pfizer Inc. (NYSE:PFE) is one of the best pharma stocks to invest in. Pfizer Inc. (NYSE:PFE) announced on December 6 results from the Phase 3 BASIS study evaluating HYMPAVZI for adults and adolescents living with hemophilia A or B with inhibitors. Pfizer’s (PFE) Pipeline and Dividend Yield Make it a Compelling Income Stock The results showed the superiority of HYMPAVZI for the improvement of bleeding outcomes in comparison with on-demand (OD) treatment with bypassing agents, reducing bleeds by 93% in ado ...

Core Viewpoint - The article discusses the global licensing agreement between Fosun Pharma's subsidiary, Yaoyou Pharmaceutical, and Pfizer for the oral GLP-1 receptor agonist project, YP05002, which aims to treat metabolic diseases including type 2 diabetes and obesity [5][7]. Group 1: Licensing Agreement Details - Fosun Pharma's Yaoyou Pharmaceutical has signed a global licensing agreement with Pfizer, granting exclusive rights for the development, production, and commercialization of YP05002 and related products [5]. - Under the agreement, Yaoyou Pharmaceutical will receive an upfront payment of $150 million and has the potential to earn up to $350 million in milestone payments based on project progress [5]. - If the product meets commercial sales targets, Pfizer will pay Yaoyou Pharmaceutical up to $1.585 billion in sales milestone payments [5]. Group 2: Product Overview - YP05002 is an oral small molecule GLP-1 receptor agonist developed by Fosun Pharma, designed to activate GLP-1 receptors to promote insulin secretion, suppress glucagon secretion, delay gastric emptying, and reduce energy intake [7]. - The candidate drug is primarily aimed at treating metabolic diseases, with potential indications including long-term weight management, type 2 diabetes, and non-alcoholic fatty liver disease [7]. - Currently, YP05002 is undergoing Phase I clinical trials in Australia [7].

Pfizer’s Tukysa, when given as part of the initial treatment for an advanced form of breast cancer, delayed tumor growth by more than eight months, according to a study that may expand its use https://t.co/XjpGcBOHzS ...